Alcohol Beverage Marketing Firm Foams Up 171% on Overhaul Plans

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

Wall Street bounced back from morning losses and closed higher after President Donald Trump denied reports he was planning to fire Fed Chair Jerome Powell, easing investor concerns over central bank stability.

Goldman Sachs (NYSE: GS) is regaining momentum as market volatility revives core strengths in trading and investment banking.

In its latest quarter, the firm posted standout performance in equities trading and saw renewed deal activity, signaling that shifting macro conditions are starting to play in its favor.

Across Wall Street, trading desks have capitalized on portfolio reshuffling tied to tariff risks, rate uncertainty, and global dislocation.

Goldman’s equities division captured record revenue, while its investment bankers saw activity pick up as pent-up demand drove new M&A and advisory flows.

Though underwriting remains uneven, deal pipelines are beginning to thaw, particularly in the Americas and Europe.

For investors, the broader message is clear: Goldman Sachs is structurally built to benefit from volatility.

While some peers heavily rely on lending or consumer segments, Goldman’s model thrives when markets are volatile and clients reposition.

Rebounding investment banking fees and strong performance in trading signal that the firm is executing well through policy-driven shifts, without waiting for a stable macro backdrop.

Those assessing Goldman’s path forward should note how its business mix is starting to pay off.

Cost discipline, flexible headcount, and strategic capital deployment are helping the firm navigate pressure points while leaning into areas of strength.

Market uncertainty may linger, but for Goldman, this environment is no longer a headwind but an opportunity to lead.

Markets don’t wait for calm—especially when political chaos takes center stage.

With Trump and Musk locked in a growing public feud, the fear of market volatility is very real.

While the headlines escalate, institutions are quietly stockpiling gold to shield against the blowback.

This free Gold IRA Survival Guide outlines a fully legal way to reposition your savings now—without taxes or penalties.

Get ahead of the next wave before the damage becomes irreversible.

[Get the Gold Protection Guide Free]

Wells Fargo (NYSE: WFC) is expanding its healthcare banking division as part of a broader push into middle-market advisory and sector-specific commercial services. 

With its longstanding asset cap officially lifted, the bank is now reallocating resources toward targeted business verticals, starting with healthcare, medical technology (medtech), and biopharma.

The expansion reflects a strategic shift inside Wells Fargo’s commercial bank.

By expanding its healthcare team across key markets, including Chicago, Florida, Northern Texas, and Southern California, the company is positioning itself to grow its share in one of the most resilient and capital-intensive sectors of the U.S. economy.

For investors, the message is about execution beyond regulatory constraints.

With the cap lifted, Wells Fargo is signaling where it intends to grow: middle-market banking, vertical specialization, and advisory-heavy services.

This plays into a broader thesis of margin expansion through client depth rather than branch-based retail growth.

Investors considering Wells Fargo’s growth plans should focus on how the company is shifting toward specialized banking.

Expanding into healthcare demonstrates that the bank is targeting clients with complex needs and long-term value, rather than relying solely on basic lending.

As competition in commercial banking intensifies, Wells Fargo is betting that deep industry knowledge will outweigh mere size.

Starting this July, big banks can legally treat gold as cash—and they’re wasting no time.

Meanwhile, millions of Americans are still heavily invested in volatile paper assets.

One economist says gold is now “the only money banks trust.”

There’s still time to catch up, using an IRS-approved method that avoids taxes or penalties.

This FREE Wealth Protection Guide explains how to move before the window closes.

[Click here to access the guide]

P.S. Every day you wait, the insiders move further ahead. Get the facts before July hits.

While mega-cap tech and AI giants dominate the headlines, a few under-the-radar names are quietly staging their moonshots.

Three companies in particular, Rezolve AI, Aurora Innovation, and Cybin Inc., are making significant moves across retail technology, autonomous transportation, and mental health therapeutics.

These aren't slow and steady plays. They're early-stage, high-risk bets on major markets still in flux.

But in each case, the progress isn't just hypothetical. Product rollouts, trial advancements, and platform expansion are already in motion, and analysts are starting to take notice.

Rezolve AI (NASDAQ: RZLV)

Rezolve's Brain Suite AI platform now supports over 16 million monthly users and more than 50 enterprise customers.

Annual recurring revenue has surpassed $70 million, and the company has recently been added to the Russell 2000 and 3000 indices.

RZLV now trades around $2.43, but eight analysts rate the stock a Buy with a $6 price target.

Some projects are as high as $10. The bullish thesis isn't just user growth.

It's the company's early traction in a $500 billion addressable market for AI-powered retail tech and services.

For investors willing to stomach volatility, the business metrics here aren't fantasy. They're early indicators of potential operating leverage.

Aurora Innovation (NASDAQ: AUR)

In May, Aurora launched a Lidar-based autonomous trucking service in Texas, the first commercial deployment of its kind.

The stock remains speculative due to limited revenue, but the operational milestone is real and tangible.

Aurora's autonomous system spans freight and ride-hailing applications. It faces competition from Uber, Tesla, and Daimler, yet five of nine analysts still rate it a Buy.

The average price target is $10.75, nearly double its current level.

Those evaluating AUR should recognize that it has transitioned from research to execution.

That puts it in a rare class among autonomy players, even if profitability remains distant.

Cybin Inc. (NYSE: CYBN)

Cybin is advancing two psychedelic-based drug candidates, CYB003 and CYB004, targeting major depressive disorder and generalized anxiety.

Neither has reached market, but Phase 2 and 3 trials are underway, and the potential addressable market is massive.

CYBN trades at $7.45, but analysts have slapped a consensus price target of $85 on it. That implies more than 1,000 percent upside.

The risk is clear, there's no revenue yet, but the conviction is also firm for a pre-revenue biotech.

If either compound clears the clinical gauntlet, Cybin could quickly shift from speculative to a serious contender in the mental health space.

Momentum Isn't Just for Big Names

The common thread here isn't hype. It's progress. Rezolve is monetizing, Aurora is operating, and Cybin is progressing through late-stage trials.

Each name offers real, high-upside exposure to transformational sectors, retail AI, self-driving transport, and psychedelic medicine.

They won't suit every investor. But for those seeking asymmetric risk-reward, these stocks may deserve a closer look before the market prices in what's happening.

👉 Click here to get our closing report to your cell for free!

LQR House Inc [YHC] $10.73 (+171.65%)

LQR House jumped after Superstate CEO Robert Leshner acquired a controlling stake and announced plans to replace the board, sparking investor optimism about a strategic turnaround.

Nuwellis Inc [NUWE] $15.95 (+131.33%)

Nuwellis rose after being granted a new U.S. patent for improving fluid accuracy in renal therapy systems, reinforcing its innovation leadership in medical technology.

Data Storage Corp [DTST] $5.30 (+56.80%)

Data Storage Corp rallied after announcing the sale of its CloudFirst unit and plans for a major share buyback, boosting investor sentiment on capital returns.

Cyclacel Pharmaceuticals Inc [CYCC] $8.20 (-33.50%)

Cyclacel Pharmaceuticals shares dropped after the company confirmed there were no material developments to justify the recent rally, dampening investor speculation.

Ardent Health Inc [ARDT] $12.01 (-13.76%)

Ardent Health tumbled after Bank of America downgraded the stock to Underperform due to risks from legislative cuts to Medicaid and ACA subsidies.  

Merit Medical Systems Inc [MMSI] $83.95 (-10.31%)

Merit Medical declined after a regulatory filing revealed hedge fund Edgestream slashed its stake by over 40%, raising concerns despite recent positive news.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.